Sage Therapeutics
Market Cap
US$5.3b
Last Updated
2021/01/17 23:08 UTC
Data Sources
Company Financials +
Executive Summary
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Sage Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SAGE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SAGE's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
0.5%
SAGE
3.5%
US Biotechs
-1.0%
US Market
1 Year Return
19.6%
SAGE
36.8%
US Biotechs
19.6%
US Market
Return vs Industry: SAGE underperformed the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: SAGE matched the US Market which returned 19.6% over the past year.
Shareholder returns
| SAGE | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.5% | 3.5% | -1.0% |
| 30 Day | 11.7% | 4.8% | 2.3% |
| 90 Day | 31.1% | 21.7% | 13.1% |
| 1 Year | 19.6%19.6% | 39.0%36.8% | 22.3%19.6% |
| 3 Year | -46.1%-46.1% | 30.5%23.6% | 45.3%35.7% |
| 5 Year | 129.3%129.3% | 43.9%33.0% | 124.8%99.8% |
Long-Term Price Volatility Vs. Market
How volatile is Sage Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Need To Know: Analysts Are Much More Bullish On Sage Therapeutics, Inc. (NASDAQ:SAGE)2 months ago | Simply Wall St
Analysts Just Made A Major Revision To Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Forecasts2 months ago | Simply Wall St
Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Have Been Cutting Their EstimatesValuation
Is Sage Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SAGE ($91.38) is trading below our estimate of fair value ($485.57)
Significantly Below Fair Value: SAGE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SAGE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SAGE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SAGE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SAGE is overvalued based on its PB Ratio (7.2x) compared to the US Biotechs industry average (4.2x).
Next Steps
Future Growth
How is Sage Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
32.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SAGE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SAGE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SAGE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SAGE's revenue (40.7% per year) is forecast to grow faster than the US market (10.3% per year).
High Growth Revenue: SAGE's revenue (40.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SAGE is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Sage Therapeutics performed over the past 5 years?
-38.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SAGE is currently unprofitable.
Growing Profit Margin: SAGE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SAGE is unprofitable, and losses have increased over the past 5 years at a rate of 38.2% per year.
Accelerating Growth: Unable to compare SAGE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SAGE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: SAGE has a negative Return on Equity (-81.74%), as it is currently unprofitable.
Next Steps
Financial Health
How is Sage Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SAGE's short term assets ($698.9M) exceed its short term liabilities ($59.7M).
Long Term Liabilities: SAGE's short term assets ($698.9M) exceed its long term liabilities ($21.4M).
Debt to Equity History and Analysis
Debt Level: SAGE is debt free.
Reducing Debt: SAGE has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SAGE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SAGE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Sage Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SAGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SAGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SAGE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SAGE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SAGE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.3yrs
Average management tenure
CEO
Barry Greene (57 yo)
0.083
Tenure
Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020. He is a Director at BCLS Acquisition Corp. He serves as Director at Sage Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & Treasurer | 7.83yrs | US$3.93m | 0.061% $ 3.2m | |
| Chief Operating Officer | 0.67yr | US$4.95m | 0.0036% $ 192.3k | |
| Senior VP | 5.33yrs | US$3.95m | 0.0030% $ 160.3k | |
| Chief Innovation Officer | 7.42yrs | US$9.90m | 0.094% $ 5.0m | |
| Chief Medical Officer | 7.5yrs | US$3.97m | 0.014% $ 757.9k | |
| President | 0.083yr | no data | no data | |
| Senior Vice President of Technical Operations | 5.33yrs | no data | no data | |
| Chief Scientific Officer | 9.17yrs | US$3.67m | 0.23% $ 12.5m | |
| Vice President of Investor Relations | 1.58yrs | no data | no data | |
| Senior Vice President of People & Organizational Strategy | no data | no data | no data | |
| Senior Vice President of Global Regulatory Affairs & Policy | 3.75yrs | no data | no data | |
| Chief Research Officer | 5.33yrs | no data | no data |
5.3yrs
Average Tenure
57.5yo
Average Age
Experienced Management: SAGE's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Innovation Officer | 7.42yrs | US$9.90m | 0.094% $ 5.0m | |
| President | 0.083yr | no data | no data | |
| Independent Chairman | no data | US$1.16m | 0.52% $ 27.7m | |
| Independent Director | 6.33yrs | US$1.15m | 0% $ 0 | |
| Independent Director | 6.67yrs | US$1.14m | 0.0018% $ 94.8k | |
| Founder & Independent Director | 9.33yrs | US$1.13m | 0.68% $ 36.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.5yrs | US$1.13m | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.5yrs
Average Tenure
59.5yo
Average Age
Experienced Board: SAGE's board of directors are considered experienced (6.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.
Top Shareholders
Company Information
Sage Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sage Therapeutics, Inc.
- Ticker: SAGE
- Exchange: NasdaqGM
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.326b
- Shares outstanding: 58.29m
- Website: https://www.sagerx.com
Number of Employees
Location
- Sage Therapeutics, Inc.
- 215 First Street
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SAGE | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jul 2014 |
| SG7 | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Jul 2014 |
| SG7 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2014 |
Biography
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intr...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/17 23:08 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.